A new study published in Frontiers in Immunology identifies a biological mechanism linking COVID-19 lung injury to increased adenocarcinoma risk...
Prof. Joseph (Yossi) Tam, DMD, PhDSchool of Pharmacy, Institute for Drug Research
The Hebrew University of Jerusalem
The Harvey M. Krueger Family Center for Nanoscience and Nanotechnology
Jerusalem, Israel
With colleagues Dr. Liad Hinden, the PhD student Radka Kočvarová, and the Tam’s team at the
School of Pharmacy at the Faculty of Medicine of the Hebrew University of Jerusalem.
MedicalResearch.com: What is the background for this study? Would you describe the condition of Metabolic dysfunction-associated steatotic liver disease (MASLD)? What causes it? Whom does it affect?
Response: MASLD, formerly known as nonalcoholic fatty liver disease (NAFLD), is the most common chronic liver disorder worldwide. It develops when fat accumulates excessively in liver cells, commonly in people with obesity, insulin resistance, high cholesterol, or diabetes. Over time, this condition can progress to inflammation, fibrosis, or cirrhosis. Despite its growing prevalence, effective pharmacological therapies remain limited, leaving a substantial unmet clinical need.
Dr. Gileles-Hillel[/caption]
Dr. Alex Gileles-Hillel MD
Founder and director of Gileles Lab
Hadassah Medical Center
Along with Dr. Joel Reiter MD from the Faculty of Medicine
Hebrew University and Senior Pediatric Pulmonologists at the Hadassah Medical Center
with Dr. David Gozal MD, MBA, PhD from Marshall University
MedicalResearch.com: What is the background for this study?
Response: Children with Obstructive Sleep Apnea (OSA) experience increased morbidity, including cognitive difficulties, daytime dysfunction, and poorer academic performance, as well as a higher risk of future cardiometabolic disease such as hypertension and obesity. In addition, pediatric OSA has been shown to impair immune responses and alter immunologic function, although the clinical consequences of these changes remain incompletely understood.